AbbVie Inc (ABBV.N)
27 May 2016
The U.S. Food and Drug Administration on Friday approved a once-monthly injection for multiple sclerosis from Biogen Inc and AbbVie Inc, with a boxed warning.
May 27 The U.S. Food and Drug Administration on Friday approved a once-monthly injection for multiple sclerosis from Biogen Inc and AbbVie Inc, with a boxed warning.
* AbbVie's Humira receives CHMP positive opinion to treat certain forms of non-infectious uveitis, a disease that can severely impact vision
* IL-23 inhibitor risankizumab induces remission in phase ii study in patients with moderate-to-severe crohn's disease
Coherus BioSciences Inc said on Tuesday the U.S. Patent and Trademark Office had agreed to review its petition to make a copy of AbbVie Inc's top-selling arthritis drug Humira.
BRIEF-AbbVie says Humira protected by many patents covering all aspects of manufacture, formulation and indications
* "we are confident in the validity of our patents and will vigorously defend them"
May 17 Coherus BioSciences Inc said on Tuesday the U.S. Patent and Trademark office had agreed to review its petition to make a copy of AbbVie Inc's top-selling artritis drug Humira.
* Paulson & Co Inc Dissolves Share Stake In Abbvie Inc - Sec filing
Belgian biotech firm Ablynx said on Thursday it used up more cash than it made in the first quarter, driven by higher external research and development costs.
AbbVie Inc placed another big bet on new cancer drugs on Thursday with a $5.8 billion acquisition that could lessen its dependence on arthritis treatment Humira, the world's top selling drug.
|Johnson & Johnson (JNJ.N)||$113.06||+0.16|
|Pfizer Inc. (PFE.N)||$34.61||+0.18|
|Novartis AG (NOVN.S)||CHF79.60||--|
|Merck & Co., Inc. (MRK.N)||$56.48||+0.09|
|Roche Holding Ltd. (ROG.S)||CHF263.40||--|
|Roche Holding Ltd. (RO.S)||CHF263.75||--|
|Abbott Laboratories (ABT.N)||$39.30||+0.41|
|Eli Lilly and Co (LLY.N)||$74.99||-0.53|
|Sanofi SA (SASY.PA)||€73.80||--|